Original Article

Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas

  1. Simona Grozinsky-Glasberg MD1,2,†,*,
  2. Dganit Barak MRS3,
  3. Merav Fraenkel MD3,
  4. Martin A. Walter MD4,
  5. Jan Müeller-Brand MD4,
  6. Joseph Eckstein MD5,
  7. Liat Applebaum MD6,
  8. Ilan Shimon MD1,2,
  9. David J. Gross MD3

Article first published online: 8 NOV 2010

DOI: 10.1002/cncr.25646

Issue

Cancer

Cancer

Volume 117, Issue 7, pages 1377–1385, 1 April 2011

Additional Information

How to Cite

Grozinsky-Glasberg, S., Barak, D., Fraenkel, M., Walter, M. A., Müeller-Brand, J., Eckstein, J., Applebaum, L., Shimon, I. and Gross, D. J. (2011), Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas. Cancer, 117: 1377–1385. doi: 10.1002/cncr.25646

Author Information

  1. 1

    Institute of Endocrinology, Beilinson Hospital, Rabin Medical Center, Tel Aviv, Israel

  2. 2

    Sackler Faculty of Medicine, Tel Aviv, Israel

  3. 3

    Endocrinology and Metabolism Service, Department of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

  4. 4

    Institute of Nuclear Medicine, University Hospital, Basel, Switzerland

  5. 5

    Imaging Department, Beilinson Hospital, Rabin Medical Center, Tel Aviv, Israel

  6. 6

    Imaging Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

  1. †

    Fax: (011) 972-3-9211403

*Institute of Endocrinology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, 49100 Israel

Publication History

  1. Issue published online: 18 MAR 2011
  2. Article first published online: 8 NOV 2010
  3. Manuscript Accepted: 16 AUG 2010
  4. Manuscript Revised: 30 JUL 2010
  5. Manuscript Received: 18 JUN 2010

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (357K)

Keywords:

  • gastrinoma;
  • somatostatin;
  • gastrin;
  • DOTATOC;
  • radioligand;
  • tumor response

PRRT seems to be a promising tool for the management of patients with inoperable or progressive metastatic gastrinomas. Early use of PRRT in these patients is recommended, before tumor progression and patient deterioration have occurred.

Abstract

BACKGROUND:

Gastrinomas, a rare group of neuroendocrine tumors, are responsible for severe peptic disease and diarrhea. Although symptomatic control may be achieved with proton-pump inhibitors (PPIs) and somatostatin analogues (SSAs), data are limited regarding the possible antitumor effect of the peptide receptor radioligand therapy (PRRT) with radiolabeled SSAs in gastrinoma patients. The goal of this study was to assess the effect of PRRT on symptoms, gastrin secretion, and tumor load in patients with progressive malignant gastrinomas.

METHODS:

We retrospectively studied 11 patients with metastatic gastrinomas followed for a mean period of 6 years. All patients were symptomatically treated with PPIs, and 9 of 11 patients received monthly injections of SSAs; all patients had an Eastern Cooperative Oncology Group score of 0-1, and received PRRT (90Yttrium- or 177Lutetium-DOTATOC) for progressive disease. Serum gastrin measurements and radiological assessment (using the Response Evaluation Criteria in Solid Tumors criteria) were performed before and every 3-6 months following PRRT.

RESULTS:

PRRT induced symptomatic improvement in all patients. The mean serum gastrin decreased significantly from 4831 mI/L to 932.6 mI/L (normal, 40-108 mI/L; P < .001). Periodic radiological surveillance showed complete response in 1 (9%) patient, partial tumor response in 5/11 (45%) patients, and tumor stabilization in 5/11 (45%) patients. In 7/11 (64%) patients, the antitumor effect of PRRT persisted after a median period of 14 months. Four of 11 (36%) patients died due to tumor progression (median time to progression, 11 months); in this group, the mean survival time after the last PRRT was 14 ± 6.9 months.

CONCLUSIONS:

PRRT seems to be a promising tool for the management of patients with inoperable or progressive metastatic gastrinomas. Cancer 2011. © 2010 American Cancer Society.

View Full Article (HTML) Get PDF (357K)